Filing Overview
Xilio Therapeutics, Inc. filed a Form 8-K dated June 15, 2022, reporting executive compensation and board changes under Item 5.02. The company is an emerging growth company, and its common stock trades on Nasdaq under the symbol XLO.
Business Context and Reporting Period
This filing does not report quarterly or annual operating results. It documents changes effective June 15, 2022, and was signed on June 16, 2022.
Financial and Liquidity Information
- The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, or other operating metrics.
- The filing text does not provide a clear value for any financial performance guidance or forecast.
Material Changes and Compensation
- Martin Huber, M.D., was promoted to President while continuing as President of Research and Development and head of research and development. He ceased serving as Chief Medical Officer in June 2022.
- Under an amended and restated employment agreement, Dr. Huber will receive an annual base salary of $500,000 and a target annual incentive equal to 50% of annualized base salary.
- Dr. Huber received an option to purchase 20,000 common shares. The option vests in equal monthly installments over four years, beginning one month after the grant date, subject to continued service.
- Robert Ross, M.D., was appointed as a Class II director effective June 15, 2022, serving until the 2023 annual meeting or earlier termination. He was also appointed to the Compensation Committee.
- Dr. Ross will receive compensation under the company’s standard non-employee director arrangements and will enter into the company’s standard indemnification agreement.
Outlook, Risks and Unusual Items
- No business outlook, clinical-development guidance, risk update, contingency, financing plan, or unusual operating item was disclosed in the filing.
- The principal governance-related items are the executive promotion, amended employment terms, equity award, and appointment of a new director.
Investor Verification Checklist
- Review Exhibit 10.1 for the complete terms of Dr. Huber’s amended employment agreement, including termination and change-in-control provisions.
- Verify the final terms and fair value of the 20,000-share option in subsequent financial statement disclosures.
- Review subsequent filings for the effect of the executive transition and new director appointment on governance and compensation.
- Consult the company’s latest periodic report for cash, liquidity, operating results, clinical-program status, and financing risks, none of which are provided in this Form 8-K.